Y-mAbs Q2 2021 Earnings Report
Key Takeaways
Y-mAbs reported net revenues of $11.0 million for the quarter ended June 30, 2021, consisting of $9.0 million of DANYELZA revenues and $2.0 million of licensing revenue. The company ended the quarter with a cash balance of $233.6 million.
DANYELZA commercialization is progressing throughout the U.S.
DANYELZA BLA submission accepted by the National Medical Products Administration of China.
Submitted the European Marketing Authorization Application to the European Medicines Agency for omburtamab in April.
Awaiting positive Type B meeting with the FDA in the third quarter to initiate rolling resubmission of the omburtamab BLA by the end of the year.
Y-mAbs
Y-mAbs
Forward Guidance
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995.